The DOI matches its Crossref record.
EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma
Open accessAbstract
EphA2 is a member of the Eph family of receptor tyrosine kinases, which interact with cell‐bound ligands known as ephrins. EphA2 expression was investigated by immunohistochemistry with an anti‐EphA2 monoclonal antibody in 80 patients with esophageal squamous cell carcinoma (ESCC) who had undergone surgery. EphA2 overexpression was positive in 40 of the 80 patients (50%). A significant correlation was observed between EphA2 expression and regional lymph node metastasis (p=0.023), number of lymph node metastases (p=0.011) and poor degree of tumor differentiation (p=0.004). The survival rates of EphA2‐positive patients were poorer than those of EphA2‐negative patients (p=0.014). The 5‐year survival rate of patients without EphA2 overexpression was 68%, whereas that of patients with EphA2 overexpression was 29%. EphA2 expression was also investigated in 7 ESCC cell lines (TE‐1, ‐2, ‐8, ‐13, ‐15, TT and TTn) and 1 immortalized human esophageal keratinocyte cell line (CHEK‐1). Western blotting revealed different levels of EphA2 expression in the 8 cell lines. EphA2 was expressed at a high level in the ESCC cell lines compared to CHEK‐1. EphA2 phosphorylation was demonstrated in all cell lines. Northern blot analysis showed that EphA2 mRNA expression in TE‐1 was greater than that in the other ESCC cell lines. The observation of small gaps on Western blot analysis of the ESCC cell lines suggests that there may be a mechanism for EphA2 regulation at the point of translation. In conclusion, EphA2 overexpression appears to be related to poor degree of tumor differentiation and lymph node metastasis in ESCC. Consequently, patients with EphA2 overexpression have a poorer prognosis than those without. EphA2 is a potential target to prevent ESCC cells spreading into the lymphatic drainage. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Melanoma: from mutations to medicine
Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012) · Genes & Development · doi:10.1101/gad.191999.112 · Cited by 496
Diverse Roles of Eph Receptors and Ephrins in the Regulation of Cell Migration and Tissue Assembly
Poliakov, A., Cotrina, M., & Wilkinson, D. G. (2004) · Developmental Cell · doi:10.1016/j.devcel.2004.09.006 · Cited by 436
Liang, K., Liu, F., Fan, J., Sun, D., Liu, C., Lyon, C. J., Bernard, D. W., Li, Y., Yokoi, K., Katz, M. H., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0021 · Cited by 364
Differential Gene Expression of Eph Receptors and Ephrins in Benign Human Tissues and Cancers
Hafner, C., Schmitz, G., Meyer, S., Bataille, F., Hau, P., Langmann, T., Dietmaier, W., Landthaler, M., & Vogt, T. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.026849 · Cited by 323
The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting
Wykosky, J., & Debinski, W. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0244 · Cited by 300
Metadata
- Authors
- Miyazaki, T., Kato, H., Fukuchi, M., Nakajima, M., & Kuwano, H.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2002-12-18
- Volume
- 103
- Issue
- 5
- Pages
- 657-663
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1964166386
- Cited by
- 214
- References
- 0
- FWCI
- 9.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. https://app.cochat.ai/papers/10.1002/ijc.10860
- The paper
- Miyazaki, T., Kato, H., Fukuchi, M., Nakajima, M., & Kuwano, H. (2003). EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. International Journal of Cancer. https://doi.org/10.1002/ijc.10860
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.